How I treat HER2-low advanced breast cancer-Reference-Cited by-同舟云学术

How I treat HER2-low advanced breast cancer

Published:2023-02 Issue: Volume:67 Page:116-123
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Schlam Ilana^ORCID,Tolaney Sara M.,Tarantino Paolo

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference67 articles.

1. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020;Lei;Cancer Commun,2021

2. Breast cancer statistics, 2019;DeSantis;CA A Cancer J Clin,2019

3. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015

4. VP6-2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up;Loibl;Ann Oncol,2022

5. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update;Wolff;J Clin Oncol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-low gastric cancer: is the subgroup targetable?;ESMO Open;2024-09

2. Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy;Pharmaceutics;2024-08-29

3. Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers;International Journal of Molecular Sciences;2024-07-05

4. A Comprehensive Review on the State of the Art of Breast Cancers in Italy;Current Medicinal Chemistry;2024-06

5. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates;American Society of Clinical Oncology Educational Book;2024-06-01